Vitality Watch

Dossier pubmed preclinical 01-jul-2026
Animal model, organoid, or cell-culture result — not yet human

Targeting YAP1-Mediated Tubular Cell Senescence to Attenuate Maladaptive Repair and Fibrotic Transition After Acute Kidney Injury.

Key claim: Sustained YAP1 overexpression drives tubular cell senescence and maladaptive repair after AKI, and post-injury senolytics or verteporfin suppress YAP1/senescence and attenuate progression to renal fibrosis.

Abstract

Maladaptive repair following acute kidney injury (AKI) is an independent risk factor for the progression to chronic kidney disease (CKD). We hypothesize that renal tubular cell senescence and subsequent epithelial-mesenchymal transition drive maladaptive repair after AKI, ultimately leading to chronic renal fibrosis. We re-analyzed single-cell RNA sequencing data (ScRNA-seq, GSE212273) from kidney tissues post-IRI. In vivo, we employed unilateral IRI and folic acid models to simulate the AKI to CKD transition. Senolytics or verteporfin were given from Day 3 post-modeling. In vitro, human renal tubular epithelial (HK-2) cells were exposed to hydrogen peroxide or TGF-β. Sustained YAP1 overexpression promoted fibroblast activation and a profibrotic phenotypic shift. AKI induced a sustained increase in YAP1 expression, which was associated with tubular cell senescence and renal interstitial fibrosis. Senolytics effectively suppressed YAP1 activity, renal senescence, and alleviated kidney fibrosis. In vitro, persistent oxidative stress upregulated YAP1 expression and induced cell senescence. Knockdown of YAP1 downregulated Hippo signaling pathway, extracellular matrix reorganization, and reduced cell senescence. Conversely, YAP1 overexpression reversed the anti-senescence effect of senolytics. Finally, pharmacological inhibition of YAP1/TEAD1 attenuated cell senescence and post-ischemic renal fibrosis. Our findings indicate that sustained YAP1 overexpression mediates tubular cell senescence, which drives maladaptive kidney repair and facilitates the AKI to CKD transition. Senolytics or verteporfin therapy initiated after the peak of AKI offers a dual benefit: it protects the regenerative capacity of tubular cells and concurrently inhibits YAP1-driven epithelial-mesenchymal transition, thereby mitigating the progression of renal fibrosis.

Why this matters

Positions YAP1/Hippo signaling as a mechanistic bridge between mechanotransduction and cellular senescence in the AKI-to-CKD transition, offering a pathway-level explanation for why senolytic clearance attenuates fibrotic maladaptive repair in the kidney. The convergence of two distinct interventions (D+Q senolysis and verteporfin YAP–TEAD inhibition) on the same senescence/fibrosis endpoint strengthens the causal link but remains entirely preclinical, with no human translation of timed post-injury senolysis for AKI yet demonstrated.

Source

Link

Briefing card

Targeting YAP1-Mediated Tubular Cell Senescence to Attenuate Maladaptive Repair and Fibrotic Transition After Acute Kidney Injury.
Stage: preclinical · pubmed · 01-jul-2026

Sustained YAP1 overexpression drives tubular cell senescence and maladaptive repair after AKI, and post-injury senolytics or verteporfin suppress YAP1/senescence and attenuate progression to renal fibrosis.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1096/fj.202503969RR

build build 880 · 2bcef25 · 2026-11-18